Singulex to Develop Assays to Assess Efficacy of Cancer Therapeutics
News Jul 30, 2008
Singulex Inc. has announced that it secured the second phase of its Fast Track Small Business Innovation Research (SBIR) contract from the National Cancer Institute (NCI). The company will use the funds to develop biomarker assays that will be useful in determining whether a potential cancer therapeutic is effective.
Because the levels of specific proteins vary depending on disease state, biomarkers, or proteins associated with a disease, can be measured to determine whether a disease is progressing.
In addition, by measuring changes to disease-associated biomarkers following treatment with a specific drug, pharmaceutical developers can assess whether a drug candidate demonstrates efficacy.
However, despite the identification and validation of cancer- associated biomarkers, technologies have not existed that allow detection sensitively enough to see the subtle changes that enable drug developers or clinicians to use biomarkers to assist in the development of medicines or to make clinical decisions.
The NCI SBIR contract will continue to support Singulex's assay development in collaboration with researchers at Washington University and Sigma Aldrich. This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261200700047C.
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
Computation and Chemistry Combine to Create World-First Auxetic ProteinNews
A team of chemists at the University of California, San Diego (UCSD) has now designed a two-dimensional protein crystal that toggles between states of varying porosity and density. This is a first in biomolecular design that combined experimental studies with computation done on supercomputers. The research, published in April 2018 in Nature Chemistry, could help create new materials for renewable energy, medicine, water purification, and more.
Fructose Formula Poses Risk to Babies With Metabolic DisorderNews
Babies with inherited intolerance of fructose face a risk of acute liver failure if they are fed certain widely available formulas containing fructose, pediatricians and geneticists are warning. Baby formula manufacturers should remove fructose or sucrose, or explicitly label their products to allow parents to avoid those sweeteners if necessary, the doctors say.
Comments | 0 ADD COMMENT
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018